Kalvista Historical Income Statement

KALV Stock

USD 10.06 0.03 0.30%

Historical analysis of Kalvista Pharmaceuticals income statement accounts such as Total Revenue of 29 K can show how well Kalvista Pharmaceuticals performed in making a profits. Evaluating Kalvista Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kalvista Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Kalvista Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kalvista Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

About Kalvista Income Statement Analysis

Kalvista Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kalvista Pharmaceuticals shareholders. The income statement also shows Kalvista investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Kalvista Pharmaceuticals Income Statement Chart

At this time, Kalvista Pharmaceuticals' Total Revenue is fairly stable compared to the past year. Gross Profit is likely to climb to about 29 K in 2024, whereas Interest Expense is likely to drop 0.00 in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kalvista Pharmaceuticals. It is also known as Kalvista Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Kalvista Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.At this time, Kalvista Pharmaceuticals' Total Revenue is fairly stable compared to the past year. Gross Profit is likely to climb to about 29 K in 2024, whereas Interest Expense is likely to drop 0.00 in 2024.

	2023	2024 (projected)
Net Interest Income	3.9M	4.1M
Non Recurring	1.3M	1.2M

Net Interest Income Non Recurring

Kalvista Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Cost Of Revenue	Interest Income	Non Operating Income Net Other	Non Recurring	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.51	0.77	0.29	-0.3	0.78	-0.83	-0.82	0.89	-0.75	0.85	-0.79	0.79	-0.78	-0.6	-0.79	0.39	0.8	0.54	-0.24	0.72	0.96	-0.24
Interest Expense	0.51		0.27	0.35	0.23	0.25	-0.35	-0.33	0.48	-0.19	0.64	-0.27	0.7	-0.22	-0.49	-0.28	-0.16	0.37	0.69	0.23	0.24	0.44	0.23
Selling General Administrative	0.77	0.27		-0.06	-0.75	0.73	-0.97	-0.98	0.93	-0.76	0.72	-0.98	0.59	-0.98	-0.73	-0.97	0.79	0.87	0.21	-0.23	0.64	0.83	-0.23
Total Revenue	0.29	0.35	-0.06		0.4	-0.09	0.08	0.08	0.06	0.17	0.15	0.15	0.36	0.12	0.31	0.16	-0.18	0.06	0.36	0.25	-0.01	0.19	0.25
Gross Profit	-0.3	0.23	-0.75	0.4		-0.49	0.63	0.68	-0.5	0.57	-0.12	0.71	0.04	0.75	0.32	0.69	-0.97	-0.68	0.41	0.43	-0.53	-0.43	0.43
Other Operating Expenses	0.78	0.25	0.73	-0.09	-0.49		-0.78	-0.79	0.77	-0.99	0.66	-0.79	0.4	-0.79	-0.58	-0.79	0.5	0.78	0.11	-0.72	0.94	0.9	-0.72
Operating Income	-0.83	-0.35	-0.97	0.08	0.63	-0.78		0.99	-0.98	0.79	-0.84	0.99	-0.69	0.98	0.82	0.99	-0.65	-0.86	-0.34	0.21	-0.65	-0.88	0.21
Ebit	-0.82	-0.33	-0.98	0.08	0.68	-0.79	0.99		-0.97	0.81	-0.8	0.99	-0.64	0.99	0.78	0.99	-0.71	-0.89	-0.27	0.25	-0.68	-0.88	0.25
Research Development	0.89	0.48	0.93	0.06	-0.5	0.77	-0.98	-0.97		-0.76	0.91	-0.96	0.78	-0.94	-0.82	-0.96	0.55	0.86	0.47	-0.14	0.64	0.91	-0.14
Ebitda	-0.75	-0.19	-0.76	0.17	0.57	-0.99	0.79	0.81	-0.76		-0.61	0.81	-0.35	0.82	0.58	0.81	-0.57	-0.79	-0.04	0.74	-0.94	-0.88	0.74
Total Operating Expenses	0.85	0.64	0.72	0.15	-0.12	0.66	-0.84	-0.8	0.91	-0.61		-0.78	0.91	-0.74	-0.86	-0.79	0.16	0.63	0.73	0.04	0.46	0.82	0.04
Income Before Tax	-0.79	-0.27	-0.98	0.15	0.71	-0.79	0.99	0.99	-0.96	0.81	-0.78		-0.6	1.0	0.79	1.0	-0.72	-0.87	-0.24	0.27	-0.66	-0.86	0.27
Total Other Income Expense Net	0.79	0.7	0.59	0.36	0.04	0.4	-0.69	-0.64	0.78	-0.35	0.91	-0.6		-0.56	-0.73	-0.62	0.04	0.45	0.9	0.3	0.24	0.69	0.3
Net Income	-0.78	-0.22	-0.98	0.12	0.75	-0.79	0.98	0.99	-0.94	0.82	-0.74	1.0	-0.56		0.73	0.99	-0.77	-0.89	-0.17	0.3	-0.68	-0.86	0.3
Income Tax Expense	-0.6	-0.49	-0.73	0.31	0.32	-0.58	0.82	0.78	-0.82	0.58	-0.86	0.79	-0.73	0.73		0.81	-0.26	-0.5	-0.56	-0.03	-0.35	-0.63	-0.03
Net Income From Continuing Ops	-0.79	-0.28	-0.97	0.16	0.69	-0.79	0.99	0.99	-0.96	0.81	-0.79	1.0	-0.62	0.99	0.81		-0.7	-0.86	-0.27	0.25	-0.66	-0.86	0.25
Cost Of Revenue	0.39	-0.16	0.79	-0.18	-0.97	0.5	-0.65	-0.71	0.55	-0.57	0.16	-0.72	0.04	-0.77	-0.26	-0.7		0.74	-0.35	-0.39	0.56	0.51	-0.39
Interest Income	0.8	0.37	0.87	0.06	-0.68	0.78	-0.86	-0.89	0.86	-0.79	0.63	-0.87	0.45	-0.89	-0.5	-0.86	0.74		0.08	-0.4	0.81	0.86	-0.4
Non Operating Income Net Other	0.54	0.69	0.21	0.36	0.41	0.11	-0.34	-0.27	0.47	-0.04	0.73	-0.24	0.9	-0.17	-0.56	-0.27	-0.35	0.08		0.49	-0.05	0.39	0.49
Non Recurring	-0.24	0.23	-0.23	0.25	0.43	-0.72	0.21	0.25	-0.14	0.74	0.04	0.27	0.3	0.3	-0.03	0.25	-0.39	-0.4	0.49		-0.81	-0.42	1.0
Net Interest Income	0.72	0.24	0.64	-0.01	-0.53	0.94	-0.65	-0.68	0.64	-0.94	0.46	-0.66	0.24	-0.68	-0.35	-0.66	0.56	0.81	-0.05	-0.81		0.84	-0.81
Reconciled Depreciation	0.96	0.44	0.83	0.19	-0.43	0.9	-0.88	-0.88	0.91	-0.88	0.82	-0.86	0.69	-0.86	-0.63	-0.86	0.51	0.86	0.39	-0.42	0.84		-0.42
Selling And Marketing Expenses	-0.24	0.23	-0.23	0.25	0.43	-0.72	0.21	0.25	-0.14	0.74	0.04	0.27	0.3	0.3	-0.03	0.25	-0.39	-0.4	0.49	1.0	-0.81	-0.42

Click cells to compare fundamentals

Kalvista Pharmaceuticals Account Relationship Matchups

Kalvista Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	879K	651K	743K	802K	816K	424.0K
Interest Expense	2.9M	9.2M	10.9M	903K	1.1M	18.0M
Selling General Administrative	10.9M	13.0M	16.6M	26.4M	30.6M	54.3M
Gross Profit	16.1M	12.6M	12.0M	(743K)	(802K)	(86.2M)
Other Operating Expenses	53.2M	57.9M	96.6M	110.9M	140.4M	147.5M
Operating Income	(29.8M)	(40.5M)	(57.9M)	(96.6M)	(110.9M)	(140.4M)
Ebit	(29.9M)	(40.5M)	(46.2M)	(82.3M)	(92.9M)	(135.1M)
Research Development	35.0M	40.2M	41.3M	70.2M	80.3M	86.2M
Ebitda	(39.7M)	(45.6M)	(81.6M)	(92.1M)	(134.3M)	(127.6M)
Total Operating Expenses	45.9M	53.2M	57.9M	96.6M	110.9M	54.3M
Income Before Tax	(20.7M)	(29.2M)	(46.2M)	(82.3M)	(92.9M)	(135.1M)
Total Other Income Expense Net	7.7M	11.3M	11.7M	14.3M	18.0M	5.3M
Net Income	(20.8M)	(29.1M)	(44.5M)	(68.5M)	(74.9M)	(126.6M)
Income Tax Expense	124K	(124K)	(1.8M)	(13.8M)	(18.1M)	(8.5M)
Net Income Applicable To Common Shares	(20.8M)	(29.1M)	(46.2M)	(82.3M)	(92.9M)	(26.1M)
Net Income From Continuing Ops	(20.8M)	(29.1M)	(46.2M)	(82.3M)	(92.9M)	(126.6M)
Cost Of Revenue	35.0K	40.2K	651K	743K	802K	86.2M
Interest Income	1.4M	1.8M	903K	1.1M	2.2M	3.9M
Non Operating Income Net Other	9.1M	11.3M	11.7M	14.3M	18.0M	(2.5M)
Net Interest Income	1.8M	903K	1.1M	2.2M	3.9M	4.1M
Reconciled Depreciation	512K	537K	564K	718K	816K	514.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kalvista Historical Income Statement

About Kalvista Income Statement Analysis

Kalvista Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Kalvista Pharmaceuticals income statement Correlations

Kalvista Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kalvista Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Kalvista Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Selling And Marketing Expenses	+ 1.0	Non Recurring
Ebit	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income
Net Income From Continuing Ops	+ 0.99	Operating Income

Ebitda	- 0.99	Other Operating Expenses
Research Development	- 0.98	Operating Income
Net Income	- 0.98	Selling General Administrative
Income Before Tax	- 0.98	Selling General Administrative
Ebit	- 0.98	Selling General Administrative
Research Development	- 0.97	Ebit